We’re covering two new FDA warning letters that were sent to Chinese API manufacturers, but as we have been digging deeper, we have discovered something even more troubling. The FDA previously caught a manufacturer on its GLP-1 Green List relabeling semaglutide obtained from another supplier, including one that wasn’t on the approved list.
Today, live from the Bask Health Studios, we’re connecting the dots between these enforcement actions, the growing demand for compounded GLP-1 medications, and reports of increased scrutiny of peptide manufacturers inside China.
Could this signal a broader crackdown on the pharmaceutical ingredient supply chain? What does it mean for patients using compounded semaglutide or tirzepatide? And how can you be sure where the ingredients in your medication actually originated?
We’re separating confirmed FDA findings from speculation and discussing what patients need to know.
📌 FDA SOURCES:
Tianjin Healthcare Warning Letter:
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tianjin-healthcare-medical-technology-co-ltd-736415-10292026
Nanjing Hanxin Warning Letter:
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026
Harbin Jixianglong Warning Letter:
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026
🔗 Follow On The Pen and join our community: https://linktr.ee/manonthemounjaro
Presented live from the Bask Health Studios. Learn more at https://bask.health
Disclaimer: I’m not a medical professional. This content is for news, education, and discussion, not medical advice. The newly published warning letters do not establish that specific GLP-1 medications were involved or that the manufacturers were working together.
